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Abstract
Current understanding of the patho-physiological events that follow acute ischaemic stroke suggests that treatment
regimens could be improved by manipulation of gene transcription and protein activation, especially in the penum-
bra region adjacent to the infarct. An immediate reduction in excitotoxicity in response to hypoxia, as well as the sub-
sequent inflammatory response, and beneficial control of reperfusion via collateral revascularization near the
ischaemic border, together with greater control over apoptotic cell death, could improve neuronal survival and ulti-
mately patient recovery. Highly significant differences in gene activation between animal models for stroke by mid-
dle cerebral artery occlusion, and stroke in patients, may explain why current treatment strategies based on animal
models of stroke often fail. We have highlighted the complexities of cellular regulation and demonstrated a require-
ment for detailed studies examining cell specific protective mechanisms after stroke in humans.
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Introduction
Ischaemic stroke is a leading cause of death and
disability worldwide. In more than 80% of cases,
it results from a transient or permanent reduction
in cerebral blood flow, caused by occlusion of a
cerebral artery by an embolus or local thrombosis
[1]. Two-thirds of patients survive the initial event
but are left with significant degrees of sensorimo-
tor, cognitive, or other impairment. The ischaemic
penumbra is a region of tissue surrounding the
ischaemic core, that has been identified for
upwards of 48h after stroke in patients, and that
has intermediate perfusion, where cells depolarize
intermittently [2-4]. Without treatment, the
penumbra often progresses to infarction owing to
the effects of ongoing excitotoxicity, spreading
depolarization and post-ischaemic inflammation.
Maintenance of perfusion pressure in this region
and hence survival of neurones within this dynam-
ic area of tissue is critical for the minimisation of
long-term damage. In this review, we have exam-
ined current features of stroke development based
on animal models or in vitro experiments, as well
as the limited work demonstrating changes
observed after stroke in humans.
Excitotoxic and inflammatory
responses
Within minutes of arterial occlusion, the affected
area of brain tissue becomes hypoxic and hypogly-
caemic. Rapid release of glutamate from presy-
naptic nerve terminals and astrocytes causes over-
stimulation of N-methyl-D-aspartate (NMDA) and
glutamate receptors [5,6]. This excitotoxicity
results in influx of Ca2+ and Na+ followed passive-
ly by movement of Cl- and water, culminating in
oedema, plasma membrane failure and neuronal
necrosis (Fig. 1). Increase in Ca2+ mediates activa-
tion of phospholipase C/A2, cyclooxygenase-2
(COX-2), and lipolysis followed by signal trans-
duction intermediates (e.g. mitogen activated pro-
tein kinase; MAP kinase), nitric oxide, and lipid
peroxidation products, respectively, resulting in
tissue damage and neuronal necrosis. Oxygen
free-radicals, Ca2+ and inducible nitric oxide syn-
thase (iNOS), as well as other hypoxia-induced
molecules, also serve as signalling molecules that
trigger the inflammatory process, which occurs
within hours of the initial insult [7]. Rapid
Induction of transcription factors occurs in dam-
aged astroglia, microglia, endothelial cells (EC),
leukocytes and peripherally derived immune cells
resulting in increased expression of inflammatory
cytokines and chemokines (Fig. 2). Nuclear factor
κB (NF- κB), a major protagonist, activates
tumour necrosis factor α (TNF- α) and inter-
leukins 1α , 1β , and 6 (IL-1α , IL-1β , IL-6) [8];
hypoxia inducible factor 1 (HIF-1) induces vascu-
lar endothelial cell derived growth factor (VEGF),
enhancing blood-brain barrier leakage and oedema
[9]; interferon regulatory factor 1 (IRF-1) stimu-
lates production of gamma interferon (γ -interfer-
on) which stimulates macrophages [10], whilst
activation of either signal transducers and activa-
tors of transcription (STAT)-1 or 3 results in over-
production of platelet-activating factor (PAF),
monocyte chemoattractant protein-1 (MCP-1) and
intercellular adhesion molecule (ICAM-1) [11].
Strong phospho-STAT-1 staining of TUNEL-posi-
tive (apoptotic) neurones has been shown in peri-
infarcted areas up to 24h following middle cere-
bral artery occlusion (MCAO) in rats [12] (Fig. 3).
Furthermore, STAT-1 knockout mice demonstrat-
ed a significantly smaller infarct volume, suggest-
ing a role in cell death [13]. Prostaglandin E2 pro-
duced via cyclooxygenase and lipolysis can also
induce inflammation by up-regulation of TNF-α
and IL-6 [14].
Up-regulation of inflammatory cytokines
induces expression of adhesion molecules includ-
ing intracellular adhesion molecule-1 (ICAM-1),
platelet EC adhesion molecule (PECAM-1) and
EC leukocyte adhesion molecule (ELAM-1) on
the EC surface, resulting in neutrophil binding and
migration to the brain parenchyma [15].
Macrophages and monocytes follow neutrophils
into the ischaemic brain, aided by chemokines
such as IL-8 and monocyte chemoattractant pro-
tein 1 (MCP-1) produced by damaged brain cells.
Within 24h after the infarct, large numbers of
inflammatory cells are found predominantly
around the infarct, and in particular in the penum-
bra where they may contribute to brain injury by
microvascular obstruction [16], and by producing
neurotoxic mediators which include reactive oxy-
gen species (ROS) and nitric oxide (NO) [17, 18].
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One study, however, demonstrated that infiltrating
leukocytes did not appear to contribute to the infarct
size after MCAO in a rat model of stroke [19].
In view of the absence of investigations into the
above parameters in human patients, it is not pos-
sible to evaluate their full significance in stroke in
man. Therapies aimed at reducing excitotoxicity
for example by attenuation of the NMDA receptor,
have shown promise, but must be delivered within
1-2h after stroke in rodent models [20].
Pharmacological interventions aimed at reducing
excitotoxicity and inflammation after stroke, that
were entered into phase III clinical trials have
been unsuccessful [21]. Inhibitors of NMDA
receptors, ion channels and glycine were ineffec-
tive probably because blockade of normal synaptic
transmission was detrimental to neuronal survival
[22]. Strategies employed to reduce the inflamma-
tory response have a longer time-window over
which they can be effective. However the sec-
ondary, beneficial effects in terms of tissue repair
and remodelling would be lost. For example,
macrophages actively remove dead cells, whilst a
reduction in growth factor release in the vicinity of
the infarct and also expression of CD34 positive
EC progenitor cells might impair revascularisation
[23, 24]. Recent reviews have focussed on the use
of inflammatory markers as predictors of brain
damage and recovery. For example, plasma IL-6
levels predict neurological deterioration and
infarct volume, whilst matrix metalloproteinase-9
(MMP-9) levels are associated with the efficacy of
thrombolytic therapy [25]. Detailed examination
of changes in expression of these markers is ham-
pered owing to the ethical difficulties in obtaining
tissue samples from patients immediately follow-
ing death from acute stroke.
Induction of neuronal apoptosis
Many susceptible neurones, particularly in the
penumbra region, undergo apoptosis, although the
mechanisms of this process are not fully under-
stood [26, 27]. Briefly, excitotoxicity, and in par-
ticular, excessive production of oxygen free-radi-
cals, results in mitochondrial permeability transi-
tion (MPT) leading to disruption of the mitochon-
drial inner membrane and activation of transcrip-
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Fig. 1 Mechanisms through which excitotoxicity results
in neuronal necrosis following acute ischaemic stroke.
Excitotoxicity results in cell depolarization, increased
Ca2+ influx and subsequent activation of intracellular sig-
nalling pathways. Excessive production of cyclo-oxyge-
nase results in release of nitric oxide, whilst phospholi-
pases activate MAP kinase, and simultaneously increase
expression of lipid peroxidation products, culminating in
neuronal necrosis. Abbreviation: iNos, inducible nitric
oxide synthase; NO, nitric oxide; PKC, protein kinase C;
MAPK mitogen activated protein kinase; PLC, phospho-
lipase C; ROS, reactive oxygen species; NMDA, N-
methyl-D-aspartate.
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Fig. 2 Inflammatory pathways associated with acute ischaemic stroke. Tissue damage caused in part by the effects
of excitotoxicity, induces expression of nuclear transcription factors such as NF- κB in a variety of parenchymal and
immune cells. Subsequent synthesis of pro-inflammatory cytokines and chemokines, in association with EC adhe-
sion molecule expression, results in migration of polymorphonuclear leukocytes and lymphocytes to the infarcted
area resulting in inflammation. Abbreviations: NF-κB, nuclear factor kappa-B; STAT, signal transducers and acti-
vators of transcription; HIF, hypoxia inducible factor; PGE2, prostaglandin E2; IRF-1, insulin responsive factor-1;
TNF-α, tumour necrosis factor-alpha; IL, interleukin; ICAM-1, intracellular adhesion molecule; ELAM-1, endothe-
lial leukocyte adhesion molecule; PECAM-1, platelet endothelial cell adhesion molecule; VCAM, vascular cell
adhesion molecule; PAF, platelet activating factor; MCP-1, monocyte chemoattractant protein; RANTES, regulated
upon activation normal T-cell expressed and secreted; iNOS, inducible nitric oxide synthase; ROS, reactive oxygen
species.
tion factors including NF- κB and activating tran-
scription factor-2 (ATF-2). This induces post-
translational modification and translocation to the
outer mitochondrial membrane, of members of the
pro-apoptotic Bcl-2 family, including Bax, Bcl-2
antagonist of cell death (Bad) and Bcl-2 homology
domain 3 (BH3)-interfering domain death agonist
(Bid), which form channels allowing the release of
cytochrome c from the mitochondrial intermem-
brane space. Release of cytochrome c is the main
trigger for mitochondrial associated apoptosis [28-
30] (Fig. 4). Cytochrome c induces oligomeriza-
tion of apoptosis activating factor-1 (APAF-1),
subsequent binding with pro-caspase-9, activation
of caspase-9 and finally binding and activation of
capase-3, which cleaves poly (ADP-ribose) poly-
merase (PARP) and inhibitor of caspase-activated
deoxyribonuclease (ICAD), amongst others, and
initiates apoptosis [28, 31].
Other components of the excitotoxic-inflam-
matory cascade can also contribute to apoptosis.
For example, activation of p53 by HIF-1 after
hypoxia, and of cysteine proteases (e.g. calpain)
following increased Ca2+ influx, leads to further
up-regulation of Bax and subsequent release of
mitochondrial cytochrome c [32, 33]. Increased
expression of pro-caspases-1, 2, 3, 6 and 8 as well
as cleaved caspase-3 occurred 12 and 24h after
MCAO in rat penumbral neurones undergoing
apoptosis [29, 31]. Cleaved caspase-3 expression
and associated neuronal apoptosis were notably
reduced in the penumbra region in the presence of
the nucleoside, citicoline (CDP-choline; Fig. 5).
Release of pro-inflammatory cytokines includ-
ing TNF- α and IL-1 activate a number of intracel-
lular signalling pathways, which result in neuronal
apoptosis. TNF- α activates TNF-receptor-associ-
ated death domain (TRADD), whilst Fas ligand,
secreted by the action of matrix metalloproteinas-
es, associates with Fas-associated death domain
(FADD) and subsequently the death domains of
these proteins interact with the death effector
domains of procaspase-8, cleaving it and in turn
activating downstream effector caspases and
apoptosis [34, 35]. The process may be partly
mitochondrial dependent, since caspase-8 can
cleave Bid, resulting in release of mitochondrial
cytochrome c and activation of pro-caspase-9 fol-
lowed by pro-caspase-3. Similarly, cytokine acti-
vation of MAP kinase pathways operating through
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Fig. 3 Expression of phosphorylated STAT-1 after
middle cerebral artery occlusion in a rat. (a) Strong
staining of neurons (arrow x 100) and in some glial
cells 12h after infarct. (b-d), gross morphological
appearance of phosphorylated STAT-1 staining, 12h,
24h, and 1 month after infarct. Staining was limited to
neurons in the old peri-infarcted area after 1 month (for
further details see reference [12]).
c-jun N-terminal kinase (JNK) and p38 MAP
kinase, is strongly associated with apoptosis [36].
A chronic increase in phosphorylation of both
JNK and p38 in reactive neurones in the penumbra
region after MCAO in the rat has been observed
[12]. The precise upstream regulators/receptors of
JNK activation after ischaemia have not been
described. However, its substrate, c-jun, as well as
its downstream regulation of p53 have been asso-
ciated with increased neuronal apoptosis in vitro
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Fig. 4 : Pathways of neuronal
apoptosis activated after acute
ischaemic stroke. Ischaemia
induces mitochondrial permeabil-
ity transition following free radi-
cal disruption, resulting in mito-
chondrial damage and subsequent
release of cytochrome c. This
activates the caspase pathway cul-
minating in cleavage of substrates
including poly (ADP-ribose)
polymerase and apoptosis.
Hypoxia, Ca2+ influx and
increased glutamate as well as
over-production of cytokines can
promote the expression of a vari-
ety of transcription factors and
signalling intermediates which
increase mitochondrial release of
cytochrome c via pro-apoptotic
members of the Bcl-2 family. A
novel pathway involving mito-
chondrial over-expression of AIF
leading to non-caspase mediated
neuronal apoptosis has recently
been identified. Red arrows signi-
fy non-capase mediated apopto-
sis. Abbreviations: AIF, apopto-
sis-inducing factor; HIF-1,
hypoxia inducible factor-1; NF
κB, nuclear factor kappa-B;
APAF-1, apoptosis activating fac-
tor-1; MKK3, map kinase kinase-
3; ATF-2, activating transcription
factor-2; CHOP-1,  growth arrest
and DNA damage-inducible gene
153, JNK, c-jun N terminal
kinase; Trk, tropomyosin-related
kinase, TNF-α, tumour necrosis
factor-alpha; IL, interleukin;
FADD, fas-associated death
domain protein; HSP, heat shock
protein; MAPKAP kinase, map
kinase-activated protein kinase;
TRADD, TNF-receptor-associat-
ed death domain.
AIF
[37-39]. Inflammatory cytokines, as well as gluta-
mate, can activate neuronal p38, stimulating tran-
scription factors, ATF-2 and growth arrest and
DNA damage-inducible gene 153, (CHOP-1) and
mediating cell death via increased cytochrome c
expression [40]. Furthermore, p38 mediated acti-
vation of MAP kinase activated protein kinase 3
(MAPKAP3) stimulates heat shock protein 27
(HSP-27) and as a consequence can up-regulate
production of inflammatory cytokines [41].
Further studies are needed to elucidate the mecha-
nisms that control this pathway and to establish
the role of p38 in neuronal death. 
Non-caspase mediated induction of apoptosis
after stroke, which involves mitochondrial release
of apoptosis-inducing factor (AIF) in ischaemic
conditions, and subsequent DNA fragmentation,
has also been described, although the exact mech-
anisms have yet to be defined [42, 43].
Deregulation of cyclin dependent kinases (CDKs)
can induce apoptosis in neurones by modulation of
cell cycle progression, however, CDK5, which is
not involved in cell cycle control, has recently
been shown to promote neuronal PC12 cell death
via activation of p53 [44, 45]. This pathway might
represent a novel mechanism involved in regula-
tion of stroke-induced neuronal apoptosis.
Neuroprotective mechanisms
The brain also activates neuroprotective mecha-
nisms in an attempt to counteract the damaging
effects of excitotoxicity and inflammation. A num-
ber of neurotrophic factors are up regulated after
ischaemic stroke, and may be synthesised and
released by neurones, infiltrating leukocytes and
microglia. In vitro studies using rat embryonic
hippocampal neurones have shown that nerve
growth factor (NGF) and brain derived neu-
rotrophic factor (BDNF), activate a signal trans-
duction pathway involving phosphor-inositol 3-
kinase (PI-3K) and Akt, which is an indirect
inhibitor of pro-apoptotic p53 and Bad. NGF and
BDNF also stimulate phospholipase C (PLC)-pro-
tein kinse C (PKC) pathways, which activate sur-
vival pathways involving NF-κB and anti-apoptot-
ic members of the Bcl-2 family [46-48]. Basic
fibroblast growth factor (FGF-2) and VEGF acti-
91
J. Cell. Mol. Med. Vol 9, No 1, 2005
Fig. 5 Expression of cleaved caspase-3 in penumbra tissue after rat middle cerebral artery occlusion (MCAO). (a)
Penumbra tissue stained with anti-caspase-3, 12h after infarct. (b) Similar tissue from a rat treated with citicoline
prior to MCAO, and (c) immediately after MCAO. A notable reduction in caspase positive neurons was seen in citi-
coline treated rats (arrows; x 100) (see reference [31]).
vate the MAP kinase pathway (ERK1/2) through
PLC or ras, stimulating production of anti-apop-
totic proteins, Bcl-2, cyclic AMP binding protein
(CREB) and NF- κB [49, 50] (Fig. 6). Indirect evi-
dence suggests that increased expression of ras
and ERK1/2 might counteract the apoptotic effects
of both p38 and JNK [51]. A strong association of
phosphorylated MAP kinase (ERK1/2) with neu-
rones in the penumbra region has been demon-
strated after stroke [12, 52]. However, the activa-
tion was transient (<24h) and a direct association
with cell survival was not demonstrated. The
mechanisms of these responses require further
investigation.
In the above studies, different models of stroke
have been employed, including the in vitro culture
of primary cells and animal models. Interestingly,
multiple and sometimes opposite functions have
been attributed to individual proteins. For exam-
ple, inflammatory cytokines such as TNF, con-
tribute to an extension of infarct size and neuronal
apoptosis in vivo [53], but also exhibit neuropro-
tection against calcium influx mediated through
NMDA receptors in vitro [8] and through activa-
tion of the EGF receptor in a rat model [54]. Other
studies in a mouse model of MCAO showed that
anti-apoptotic protection through Bcl-2 resulted in
a build up of pro-caspase-9 and promoted cell
death, suggesting that simple therapeutic inhibi-
tion of individual signalling intermediates may not
be sufficient to provide neuroprotection [55].
Similarly, glutamate induced excitotoxicity and
neuronal damage in vitro, were reduced by
inhibitors of MAP kinase, which is surprising,
since growth factor stimulation of MAP kinase is
neuro-protective [56]. Growth factor withdrawal
is also associated with activation of apoptotic
pathways, suggesting that modulation of either
levels and mixtures of cytokines, the time of
expression, or the signal transduction pathways
they initiate could be sufficient to affect neuronal
survival [57].
Since there have been very few studies describ-
ing changes in expression of pro- and anti-apop-
totic molecules following ischaemic stroke in
man, therapeutic neuroprotection has so far been
based on results from animal models of stroke,
such as those described above. These treatments
have had very limited success in human trials [58,
59]. Success of these agents is time-dependent,
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Fig. 6 Potential mechanisms of neuroprotection after
acute ischaemic stroke. Inflammation results in increased
expression of neurotrophic factors including NGF and
BDNF, which bind to the TrkA and neurotrophin receptors
respectively and activate a signalling pathway through PI-
3K and Akt inhibiting the action of pro-apoptotic proteins
p53 and Bad, and inducing pro-survival factors NF-κB and
Bcl-2 expression. Growth factors produced during inflam-
mation and hypoxia, together with BDNF activate conven-
tional MAP kinase pathways, which oppose the effects of
pro-apoptotic JNK and p38 signalling, and also stimulate
further expression of survival factors such as CREB, NF
κB and Bcl-2. Abbreviations: NGF, nerve growth factor;
BDNF, brain-derived neurotrophic factor; TrkA, tyrosine
kinase A; PI-3K, phospho- inositol-3 kinase; BAD, Bcl-2
antagonist of cell death; NF-κB, nuclear factor-kappa B;
PLC, phospholipase C, NTR, neurotrophin; FGF-2, fibrob-
last growth factor-2; VEGF, vascular endothelial cell
growth factor; Grb2, growth factor receptor-bound protein-
2; SOS, son of sevenless; JNK, c-jun N-terminal kinase;
CREB, cyclic AMP binding protein; ERK1/2, early
response kinase 1/2; PKC, protein kinase C.
with trials suggesting treatment times in man as
being too late if following predictions from animal
models. The potential benefits of neuroprotective
therapeutic intervention have recently been high-
lighted by the positive results seen using novel
protein transduction technology in preclinical
studies [60]. Protein transfer domains (derived
from HIV-1 Tat), attached to Bcl-xl, were effec-
tively delivered across the blood-brain barrier and
significantly reduced infarct size and caspase acti-
vation in a mouse model of stroke [61]. A system-
atic study of neuroprotective and apoptotic protein
de-regulation in patients after stroke is still lack-
ing. However, chronically increased phospho-
ERK1/2 expression has been reported in surviving
cortical neurons in the penumbra region of
patients following ischaemic stroke [62] (Fig. 7).
Revascularisation and tissue
reperfusion after stroke
Reperfusion and collateral revascularization of
potentially viable tissue could be an important fac-
tor in determining patient recovery and therefore
thrombolysis may form part of a useful treatment
regime. Krupinski et al [63-65] demonstrated
increased angiogenesis that was associated with
tissue survival, in the penumbra tissue of patients
after acute ischaemic stroke (Fig. 8).
The revascularization process after MCAO has
been described in a rat model using brain vascular
casts [66]. The data suggested that new blood ves-
sels initiated through vascular buds, formed regu-
lar connections with intact microvessels within
one week of ischaemia, the patterns being similar
to those seen in the normal brain (Fig. 9). This
group and others showed that apoptosis within
damaged EC might be necessary to regulate the
process [66, 67]. It has been reported that arterio-
lar collateral growth and new capillaries supported
restored perfusion in the ischaemic border after
ministroke [68], and in the cortical region after
photothrombotic ring stroke in rats [69].
Significant quantities of angiogenic growth
factors are secreted by inflammation associated
infiltrating macrophages, leukocytes and damaged
blood platelets, which probably helps to maintain
increased circulatory expression after stroke [70,
71]. Specific up-regulation of angiogenic factors
(e.g. VEGF, FGF-2), occurs in EC, in response to
hypoxia associated activation of second messen-
ger pathways involving ERK1/2, p38 and JNK
MAP kinases [72, 73], (Fig. 10). Cytokines,
including TNF- α and IL-1, released following
stress and inflammation, induce transcription of
growth factor mRNA through the same signalling
intermediates [74]. These cytokines also stimulate
increased expression of angiopoietin-1.
Angiopoietin-1, which binds to the EC-specific
receptor, tyrosine kinase with immunoglobulin
and epidermal growth factor homology domains 2
(Tie2), can mediate cell survival through PI-3K
and the serine-threonine kinase Akt (or Protein
Kinase B), and cell migration via growth factor
receptor-bound protein (Grb7)-focal adhesion
kinase (FAK), and has been shown to reduce cere-
bral blood vessel leakage and ischaemic lesion
volume after focal cerebral embolic ischaemia in
mice [45, 75].
VEGF, perhaps the most potent angiogenic fac-
tor, is up regulated within hours of stroke and has
a strong influence on the growth of new blood ves-
sels after ischaemia [76, 77]. Unfortunately, its
function as a vascular permeability factor also
means that localization in the primary ischaemic
core causes blood-brain barrier leakage resulting
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Fig. 7 Intensive staining of phospho-ERK1/2 in neurons
arrows of grey matter penumbra in tissue from a patient 3
days after acute ischaemic stroke (see reference [62]).
in brain oedema [9]. The role of endogenously
produced transforming growth factor-β (TGF-β)
after stroke remains to be elucidated, however,
injection of a selective antagonist (T beta RII-Fc)
caused an increase in infarct volume following
induction of cerebral focal ischaemia in rats [78].
Injection of TGF-α into rat brains following MCA
occlusion resulted in a significant decrease in
stroke volume [54]. This effect was ameliorated
following pre-injection with the specific epider-
mal growth factor (EGF) receptor inhibitor 4,5-
dianilinophthalimide (DAPH), suggesting that
TGF-α was operating through the EGF receptor.
Typical growth factor induced signal transduc-
tion pathways bind via the Src-homology-2 (SH2)
domains of transmembrane tyrosine kinase recep-
tors [79], resulting in activation of signal transduc-
tion cascades, which may be complicated by their
integration at various levels [80]. EC proliferation,
an important feature of angiogenesis, involves
activation of PLCγ, Src, PKC and Ras, culminat-
ing in the stimulation and subsequent nuclear
translocation of MAP kinase (ERK-1/ERK-2) and
rapid phosphorylation of early response genes
such as Elk-1 [79, 81, 82]. EC can express two
forms of the VEGF receptor VEGFR-1 (KDR) and
VEGFR-2 (Flt) (reviewed in [83]). However, only
cells expressing VEGFR-2 activated MAP kinase,
were able to undergo cell proliferation. EC migra-
tion also, can be induced through MAP kinases
[84], or by a separate transducing mechanism
involving membrane bound heterotrimeric G-pro-
teins coupled to phospholipase A2 and arachidon-
ic acid (not shown in Fig. 10). Rho GTPases, acti-
vated through multiple types of receptor (e.g. G-
protein-coupled, tyrosine kinase and cytokine
receptors) stimulate cell migration in concert with
ras [85]. Activation of p38 and JNK MAP kinases
in vitro results in stabilization of growth factor
mRNA as well as promotion of EC migration.
Studies have shown that inhibition of FGF-2 stim-
ulated p38, enhanced neovascularization in the
chick chorioallantoic membrane. However, the
vessels displayed abnormal features of hyperpla-
sia, suggesting an important role for p38 in the
regulation of angiogenesis [86]. Inhibition of
FGF-2 induced p38 MAP kinase in mouse spleen
EC, prevented tube formation in type I collagen
gels, and attenuated both proliferation and migra-
tion of those cells [87]. Many of the same angio-
genic factors (e.g. platelet derived EC growth fac-
tor; PDGF, FGF-2 and endothelin-1- ET-1) pro-
duced during strokes can also induce proliferation
of smooth muscle cells, which have an important
role in the revascularization process [88].
Although increased expression of growth factors
and cytokines has been shown in a variety of ani-
mal models following acute stroke, many of the
signalling pathways described above, that are
responsible for revascularization have only been
subjectively proposed on the basis of in vitro cul-
ture studies.
Activation of MAP kinase may have a pivotal
role in stroke-associated abrogation of apoptosis,
controlling angiogenesis and promoting VEGF
expression through HIF-1 [72]. It has been shown
that a transient (<24h) increase in expression of
phosphorylated p38, p-ERK1/2 and JNK MAP
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Fig. 8 This figure shows high microvessel density in
infracted brain tissue from a patient with acute
ischaemic stroke which has been shown to correlate
with good prognosis (see references [64, 65]).
kinases, in penumbra associated EC following
MCAO in a rat model. Selected over-expression of
these proteins might be involved in cellular sur-
vival and revascularization [12, 62].
Endothelial cell apoptosis
EC apoptosis can occur in response to the hypox-
ic conditions associated with stroke (Fig. 11).
Oxygen-glucose deprivation induces iNOS
expression, thereby increasing concentrations of
nitric oxide and peroxynitrites associated with
apoptosis [89]. The inflammation-associated
increase in TNF-α expression, was accompanied
by an increased NO expression in murine vascular
EC through an undetermined mechanism [90], and
also induced expression of reactive oxygen
species through the Rho family GTP binding pro-
tein Rac1, and during reperfusion through a path-
way incorporating PKC [91, 92]. Excitotoxicity
induced mitochondrial damage may result in acti-
vation of caspase 9, and initiate apoptosis by the
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Fig. 9 Scanning electron microscopy of the vascular cast from normal rat brain and following MCAO in a rat model
of stroke. (a-c), casts from normal adult rat (size demonstrated by bar) showing leptomeningeal (large arrows) and small
penetrating arterioles (small arrows) (a). An extensive micro-vascular network interconnects radially arranged penetrat-
ing arterioles and venules (b-c). (d-f), vascular cast after MCAO, showing areas of infarction where no blood vessels are
visible (d-e). The regular pattern of micro-vasculature is also lost in the vicinity of the infarction. In 'f', apparently
stressed micro-vessels are visible 24h after stroke (arrow). (g-j) Three days after MCAO, the first vascular buds are vis-
ible at many sites (arrows). The smallest micro-vessels formed connections with the surrounding proliferating vessels
(h-j). In animals perfused for 2 weeks after MCAO, some micro-vessels had collapsed close to the budding vessels, sug-
gesting that no-reflow phenomenon may have occurred (k). Both in the cortical regions and deeply within the brain vas-
culature, small micro-vessels formed very dense nests of proliferation usually around larger micro-vessels (i). These con-
glomerates increased in size with time of survival (see reference [66]).
same mechanisms as for neurones [93]. Mediators
of apoptosis and their associated second messen-
ger pathways have not been fully described after
stroke. Increased expression of JNK and p38 dur-
ing hypoxia-reoxygenation in human cerebral
microvessel EC, was associated with activation of
caspase-3 and apoptosis [94]. Other mechanisms
for inducing apoptosis exist. For example, hydro-
gen peroxide induced apoptosis in pulmonary vas-
cular EC through apoptosis signal-regulating
kinase (ASK-1) mediated activation of JNK and
p38 [95]. The localization, mechanism of stimula-
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Fig. 10 Possible mecha-
nisms of angiogenesis fol-
lowing acute ischaemic
stroke. Growth factors
including FGF-2, PDGF,
VEGF and TGF-β are
released during inflamma-
tion and hypoxia by brain
parenchymal and immune
cells. These angiogenic fac-
tors promote EC prolifera-
tion through conventional
ras-ERK1/2 pathways and
migration via CD42-
p38/JNK. Inflammatory
cytokines such as TNF-α
and IL-8 can also activate
p38 and JNK pathways.
Furthermore, cytokine-
induced expression of
angiopoietin, can stimulate
EC migration through FAK
and survival through PI-3K-
AKT. Abbreviations: HIF-
1α, hypoxia-inducible fac-
tor-1 alpha; NF-κB, nuclear
factor kappa-B; FGF-2,
fibroblast growth factor-2;
PDGF, platelet-derived
growth factor; TGF-β,
transforming growth factor-
beta; VEGF, vascular
endothelial cell growth fac-
tor; PLC-γ, phospholipase
C-gamma; PKC, protein
kinase C, Grb2, growth fac-
tor receptor-bound protein-
2; SOS, son of sevenless;
ERK, early response kinase;
MKK5, map kinase kinase-
5; JNK, c-jun N-termimal
kinase; IL, interleukin; PI-
3K, phosphoinositol-3
kinase; FAK, focal adhesion
kinase.
tion and time-course of activation of MAP kinases
may be critical in determining the effect on sur-
vival and growth.
Several growth factors and associated sig-
nalling pathways have been identified in human
stroke. Enhanced expression of the growth factors
like VEGF [10, 62, 96], PDGF- β [63], TGF- β
[97] and FGF-2 [Issa et al, unpublished data] has
been demonstrated in penumbra tissue undergoing
angiogenesis, suggesting that these factors might
indirectly be determinants of neuronal survival
after stroke. Increased phosphorylation of ERK1/2
has been reported to be localized around blood
vessels in the penumbra, associated with an
increased expression of VEGF and tyrosine phos-
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Fig. 11 Pathways of EC apoptosis following acute ischaemic stroke. The mechanisms through which EC undergo apop-
tosis following infarct have not been described in detail. In vitro data suggests stimulation of p38 and JNK MAP kinase
pathways can induce activation of caspase-3 and stimulate EC apoptosis following hypoxia and in the presence of ROS.
Increased expression of ROS and NO following stroke can lead directly to mitochondrial damage and further activation
of the pro-apoptotic caspase cascade. Abbreviations TNF-α tumour necrosis factor-alpha; JNK, c-jun N-termimal
kinase; NOS, nitric oxide synthase; NO, nitric oxide; PKC, protein kinase C; ROS, reactive oxygen species.
Fig. 12 Micro-vascular EC in penumbra tissue strongly
stained in a patient who survived 4 days following acute
ischaemic stroke (see reference [62]).
phorylated proteins in patients after stroke [62]
(Fig. 12). VEGF may warrant further clinical
investigation, since it was recently shown to
enhance neuroprotection, neurogenesis and angio-
genesis after MCAO in a rat model of stroke [76].
Preclinical studies have demonstrated both a
reduction in stroke size, and recovery of sensori-
motor function of impaired limbs after administra-
tion of FGF-2, and clinical trials of its intravenous
administration as a cytoprotective agent in acute
stroke have been performed [98]. Hepatocyte
growth factor was strongly angiogenic, signifi-
cantly reduced neurological deficit, and at the
same time, did not induce cerebral oedema after
gene transfection prior to MCAO in rat [99], sug-
gesting its relevance to the progression of stroke.
Conclusions
A number of studies have examined gene regula-
tion after ischaemic stroke in an animal model,
using cDNA printed microarrays [100, 101], and
have demonstrating deregulation of numerous
novel genes. We have recently conducted a
detailed series of microarray studies comparing
global gene regulation in brain tissue following
acute large vessel ischaemic stroke in patients sur-
viving for 2 days-7 weeks, and following MCAO
in a rat model, 1hour-21 days after stroke. The
unpublished results showed notable differences in
gene expression and time of expression between
the human disease and the animal model. These
studies suggest there is a need to determine the
time course of expression of neuro-regulatory,
angiogenic and EC apoptotic factors and their
associated enzymes after ischaemic stroke in man.
Non-therapeutically stimulated angiogenesis
occurs only 3-4 days after stroke, which is beyond
the period of reversible changes in ischaemic
penumbra, recognised as a therapeutic window in
ischaemic brain. Owing to the complexity of phys-
iological regulation of blood vessel formation,
involving numerous critical growth factors
expressed differentially in time, space and concen-
tration, ongoing therapeutic efforts using single
agents, and aimed at treatment of vascular
ischaemic disease are of limited potential. Growth
factor induced signal transduction e.g. via JNK
and p38 MAP kinase stimulates EC growth and
might be beneficial. The same factors may stimu-
late apoptosis in neurons. It is likely that optimum
conditions for angiogenesis together with subse-
quent neuronal protection may require therapeutic,
cell specific, modulation of these intermediates,
together with their stimulating factors.
Optimization of therapeutic treatments might
involve a complex series of interventions begin-
ning with self-treatment to reduce excitotoxicity-
associated cell death within minutes of infarction.
A cocktail of drugs could then be administered
within the first few hours of illness to reduce
inflammation, but at the same time, maintain neu-
ronal viability with neurotrophins and stimulate
growth factor-induced angiogenesis. Perfusion
pressure in the penumbra region could be
increased using thrombolytic therapy and suscep-
tible neurons could be protected from apoptosis by
viral transfer of genes such as Bcl-2 [102, 103]. In
the recent past, progress in the ability to transfer
proteins by protein transduction technology across
the blood-brain barrier, as well as advances in neu-
rological gene therapy, which has shown that brain
defects in experimental disease models can be pre-
vented and corrected [104, 105], indicates that suf-
ficient information is now available to contem-
plate radical changes in treatment strategies in
patients with stroke.
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